Drug Delivery Technology

Innovative Platforms to Support Bioavailability and Patient Experience

TSRL’s drug delivery technologies are developed with a science-first mindset, focused on solving formulation challenges and improving patient outcomes. Our team explores novel approaches that address solubility, permeability, stability, and usability concerns early in the development process.

These technologies are designed to complement therapeutic goals, streamline administration, and support both Sponsors and patients throughout the drug development journey.

 

Microarray Patch (MAP) Technology

Our MAP technology provides a self-administered, hydrogel-based delivery system that avoids the need for traditional injections. This approach is especially useful for suboptimal drug products where compliance, stability, or dosing consistency is a concern.

MAP benefits include:

  • Drug-releasing reservoir activated by skin application

  • Systemic delivery without a clinic visit

  • Improved patient compliance and convenience

MAP technology represents a practical delivery alternative for therapies that require better ease-of-use or are limited by traditional routes.

 

Why Teams Choose TSRL’s Drug Delivery Technologies

  • Solutions for difficult compounds, designed to support low-permeability, poorly soluble, and unstable drug candidates.

  • Support with early-stage planning, aligning delivery strategies with timelines, therapeutic goals, and regulatory needs.

  • Options that improve patient experience, including technologies that promote compliance and reduce the burden of administration.

  • A partner who thinks beyond the data, combining scientific insight with hands-on development support.

 

Clients are Saying

 

“We are very excited to collaborate with TSRL as they have de-risked certain technical and manufacturing aspects of the microneedle patch and by sharing our resources it will allow PharmaTher to expedite the clinical and commercial development of the microneedle patch with ketamine and other psychedelics.”

Fabio Chianelli, CEO
PharmaTher

 

Let's Talk About Your Program

Connect with a TSRL scientist to learn how we can support your goals with strategic, science-driven solutions by filling out this form.